Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients

Oncotarget

Volumn 9, Issue 26, 2018, Pages 18529-18539

  Vollbrecht, Claudia ^a,b   Lehmann, Annika ^a   Lenze, Dido ^a   Hummel, Michael ^a,b  

^a BERLIN INSTITUTE OF HEALTH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CfDNA; Liquid biopsy; NGS; NSCLC; T790M

Indexed keywords

CELL FREE NUCLEIC ACID; CIRCULATING CELL FREE DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; DNA EXTRACTION; DNA SEQUENCE; GENE FREQUENCY; GENE MUTATION; HOTSPOT MUTATION; HUMAN; INDEL MUTATION; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIQUID BIOPSY; MEASUREMENT ACCURACY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; POINT MUTATION; POLYMERASE CHAIN REACTION; RELIABILITY; SENSITIVITY AND SPECIFICITY; UNIQUE MOLECULAR IDENTIFIER; VALIDATION PROCESS;

EID: 85044998955     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.24908     Document Type: Article

References (31)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-39. https://doi.org/10.1056/NEJMoa040938
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-500. https://doi.org/10.1126/ science.1099314
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-57. https://doi.org/10.1056/ NEJMoa0810699
4. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13:239-46. https://doi.org/10.1016/S1470-2045(11)70393-X
5. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352:786-92. https://doi.org/10.1056/NEJMoa044238
6. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009; 10:281-9. https://doi.org/10.3816/ CLC.2009.n.039
7. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3:75ra26. https://doi.org/10.1126/ scitranslmed.3002003
8. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372:1689-99. https://doi.org/10.1056/ NEJMoa1411817
9. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4:1046-61. https://doi.org/10.1158/2159-8290.CD-14-0337
10. Jiang T, Zhou C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitorresistant non-small cell lung cancer. Transl Lung Cancer Res. 2014; 3:370-2. https://doi.org/10.3978/j.issn.2218-6751.2014.08.02
11. Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, et al. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016. https://doi.org/10.18632/ oncotarget.11692
12. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013; 31:17-22. https://doi.org/10.1200/ JCO.2012.43.1718
13. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007; 635:105-17. https://doi.org/10.1016/j. mrrev.2006.11.002
14. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, Hadfield J, May AP, Caldas C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012; 4:136ra68. https://doi.org/10.1126/ scitranslmed.3003726
15. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32:579-86. https://doi.org/10.1200/JCO.2012.45.2011
16. Ye X, Zhu ZZ, Zhong L, Lu Y, Sun Y, Yin X, Yang Z, Zhu G, Ji Q. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact? J Thorac Oncol. 2013; 8:1118-20. https://doi.org/10.1097/ JTO.0b013e31829f691f
17. Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen W, Ye H, Liu JH, Wei S, Zhao MY, Wu WJ, Su XX, Shi R, et al. Circulating tumor DNA identified by targeted sequencing in advancedstage non-small cell lung cancer patients. Cancer Lett. 2016; 370:324-31. https://doi.org/10.1016/j.canlet.2015.11.005
18. Cai X, Janku F, Zhan Q, Fan JB. Accessing Genetic Information with Liquid Biopsies. Trends Genet. 2015; 31:564-75. https://doi.org/10.1016/j.tig.2015.06.001
19. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10:472-84. https://doi.org/10.1038/ nrclinonc.2013.110
20. Kivioja T, Vaharautio A, Karlsson K, Bonke M, Enge M, Linnarsson S, Taipale J. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. 2011; 9:72-4. https://doi.org/10.1038/nmeth.1778
21. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, Rio Frio T, Pierron G, Callens C, Bieche I, Saliou A, Madic J, Rouleau E, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol. 2015; 9:783-90. https:// doi.org/10.1016/j.molonc.2014.12.003
22. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14:985-90. https:// doi.org/10.1038/nm.1789
23. Ghoneim DH, Myers JR, Tuttle E, Paciorkowski AR. Comparison of insertion/deletion calling algorithms on human next-generation sequencing data. BMC Res Notes. 2014; 7:864. https://doi.org/10.1186/1756-0500-7-864
24. Bartels S, Persing S, Hasemeier B, Schipper E, Kreipe H, Lehmann U. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection. J Mol Diagn. 2017; 19:722-32. https://doi.org/10.1016/j. jmoldx.2017.05.008
25. Volckmar AL, Sultmann H, Riediger A, Fioretos T, Schirmacher P, Endris V, Stenzinger A, Dietz S. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. Genes Chromosomes Cancer. 2018; 57:123-39. https://doi. org/10.1002/gcc.22517
26. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Janne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34:3375-82. https://doi. org/10.1200/JCO.2016.66.7162
27. Tug S, Helmig S, Deichmann ER, Schmeier-Jurchott A, Wagner E, Zimmermann T, Radsak M, Giacca M, Simon P. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev. 2015; 21:164-73
28. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014; 6:224ra24. https://doi. org/10.1126/scitranslmed.3007094
29. Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW. BEAMing up for detection and quantification of rare sequence variants. Nat Methods. 2006; 3:95-7. https://doi. org/10.1038/nmeth850
30. Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res. 2014; 4:411-35
31. Buder A, Hochmair M, Holzer S, Mohn-Staudner A, Errhalt P, Bundalo T, Schenk P, Setinek U, Burghuber O, Pirker R, Filipits M. P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC. In: Adjei AA, ed. International Association for the Study of Lung Cancer (IASLC). (Yokohama, Japan: Journal of Thoracic Oncology), 2017; S1205-S6